TABLE 1.
Name | Type | Structure | Ki/IC50/EC50 value for MC4R | Reference |
---|---|---|---|---|
Sodium 4‐phenylbutyrate (4‐PBA) | Chemical chaperone | — | 70 , 71 | |
THIQ |
Pharmacological chaperone agonist |
IC50 1.2 nM | 75 | |
NPB | Pharmacological chaperone antagonist | Ki 2.4 nM | 72 | |
Ipsen 17 | Pharmacological chaperone antagonist | Ki 0.96 nM | 73 | |
RO‐273225 (Butyr‐His‐D‐Phe‐Arg‐Trp‐Sar‐NH2) | Linear peptide | EC50 1 ± 0.3 | 113 | |
PL‐8905 | Cyclic peptide | High affinity | 49 | |
Setmelanotide | Cyclic peptide |
EC50 0.27 nM |
36 | |
2Me‐2H tetrazole derivative | Nonpeptide agonists | High affinity | 101 | |
Piperazine benzenes | Nonpeptide agonists | Ki 11 nM | 103 | |
1,3,4‐trisubstituted‐2‐oxopiperazine | Nonpeptide agonists | Ki 5.7 nM | 104 |
Abbreviations: EC50, half maximum effective concentration; IC50, half maximum inhibitory concentration; Ki, inhibition constant; MC4R, melanocortin‐4 receptor; THIQ, N‐[(3R)‐1,2,3,4‐Tetrahydroisoquinolinium‐3‐ylcarbonyl]‐(1R)‐1‐(4‐chlorobenzyl)‐2‐[4‐cyclohexyl‐4‐(1H‐1,2,4‐triazol‐1‐ylmethyl) piperidin‐1‐yl]‐2‐oxoethylamine.